Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Calidi Biotherapeutics ( (CLDI) ) has issued an update.
In the second quarter of 2025, Calidi Biotherapeutics reported significant progress in its operations, including the presentation of preclinical data on its lead compound CLD-401 and receiving FDA Fast Track Designation for CLD-201. The company also raised $4.6 million through a warrant inducement offering, strengthening its financial position amid a challenging biotech financing environment. Despite a net loss of $5.7 million, Calidi continues to advance its innovative therapies targeting high unmet medical needs in cancer treatment.
The most recent analyst rating on (CLDI) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.
Calidi Biotherapeutics’ overall stock score reflects significant financial and technical challenges, typical of a developing biotech company. While corporate events bring positive leadership changes and strategic advancements, the company’s lack of revenue, high leverage, and bearish technical indicators weigh heavily on its score.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage immuno-oncology company based in San Diego, California, focused on developing targeted therapies that deliver genetic medicines to distal disease sites. The company utilizes its proprietary Redtail platform, which features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites, aiming to shield the virus from immune clearance and effectively reach tumor sites.
Average Trading Volume: 1,457,830
Technical Sentiment Signal: Sell
Current Market Cap: $17.78M
For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.